Sector News

Takeda CEO reassures investors worried the math on its $62B Shire buyout doesn't add up

June 28, 2018
Life sciences

It turns out that investor opposition to Takeda’s $62 billion buyout of Shire comes down to blood. Investors are concerned that competition to Shire’s hemophilia drugs for blood disease cut its revenues so much that it will make the deal unsustainable.

The Financial Times, citing sources, reported that during a recent investor meeting, Takeda CEO Christophe Weber was pressed on how sustainable sales from Shire’s hemophilia unit will be in the face of competition from new generation drugs.

The unit accounts for a quarter of the Ireland-based drugmaker’s revenues, but analysts have said that they expect Roche’s Hemlibra, which is now under FDA priority review for a label expansion, will quickly erode much of Shire’s sales, the Financial Times reported. Unlike hemophilia drugs currently on the market, Hemlibra is not expected to require patients to undergo daily or weekly infusions of replacement Factor VIII.

“We continue to expect Hemlibra to become the new standard of care in the treatment of haemophilia A … and currently model peak sales of $5 billion for the product,” Jefferies analyst Ian Hilliker, told the newspaper.

Hemlibra is currently approved only for treating patients who develop factor VIII inhibitors during treatment but Roche is seeking a label expansion to those patients without the inhibitors, a much larger patient population. Data from a recent study showed Hemlibra significantly cut bleeding incidents in those patients.

Adding to its appeal is the fact that Roche has priced Hemlibra at $450,000, a significant discount to Shire’s Adynovate, a long-lasting replacement Factor VIII treatment, which bears a price tag of about $537,000 a year.

Weber tried to reassure doubtful investors, the Financial Times said, by insisting that Takeda built the impact from pending competition into its financial model for the deal.

But they also are worried about the potential for new gene-based treatments under development by Pfizer and others to grab market share if approved. These treatments are designed to fix the genetic problem that underlies the disease. While acknowledging Takeda is not going to be a leader in gene therapy, Weber pointed out the gene technology is complicated to develop, the Financial Times reported.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).